(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
AIM - WINNERS
Galantas Gold, up 20% at 18.50p, 12-month range 7p-27p. The Omagh gold mine owner says it has reached a commercial blasting agreement with the police service of Northern Ireland. The new arrangements are designed to permit underground blasting to be expanded to achieve commercial production levels.
European Metals Holdings, up 13% at 66.60p, 12-month range 8.2p-84p. The mineral exploration and development company says it has received firm commitments for a private placement worth AUD7.1 million, equivalent to around GBP4 million. EMH has received commitments for a placement of 6.5 million Crest depositary interests at an issue price of AUD1.10 each. The proceeds of the placement will assist in the further development of the Cinovec lithium project and further general working capital.
Brave Bison, up 12% at 1.57p, 12-month range 0.67p-1.59p. The social media and marketing group says it has been selected by Hero Caribbean Premier League to manage the cricket organisation's YouTube content, channels, rights, monetisation and audience development. Under the new contract, both companies will work to grow and optimise Hero Caribbean's YouTube channel which currently has 823,000 subscribers. Brave Bison will act as a consultant on best practices and creative and innovative content strategies.
STM Group, up 11% at 29.92p, 12-month range 18p-42p. The financial services provider says it expects its earnings for 2020 to surpass 2019. STM expects 2020 revenue of GBP24.0 million, earnings before interest, tax, depreciation and amortization of GBP3.6 million, and pretax profit of GBP2.0 million. For comparison, in 2019, STM posted pretax profit of GBP3.9 million on revenue of GBP23.3 million. Ebitda for 2019 was GBP3.5 million.
Harvest Minerals, up 11% at 2.67p, 12-month range 1.67p-4.38p. The remineraliser producer says 2020 KP Fertil orders totalled 54,155 tonnes, beating its 50,000 tonnes target for the year. 2021 sales guidance is targeted at 80,000 tonnes.
AIM - LOSERS
Scancell Holdings, down 7.0% at 13.25p, 12-month range 4.15p-20.9p. The immunotherapies developer notes the end of its clinical development partnership with charity Cancer Research UK for SCIB2, a treatment for patients with solid tumours. Scancell said that due to the impact of the Covid-19 pandemic and the re-evaluation by Cancer Research UK's centre for drug development of their collaboration model, "the parties have come to a mutual agreement" to end their partnership for the company's 'ImmunoBody' vaccine, or SCIB2.
By Arvind Bhunjun; firstname.lastname@example.org
Copyright 2021 Alliance News Limited. All Rights Reserved.